NCT06006624: Exparel vs Block for ACL Reconstruction

Summary

Liposomal bupivacaine or Exparel (Pacira Biosciences) is a long-lasting nonopioid analgesic that was initially utilized as an infiltrative agent but has more recently become U.S. Food and Drug Administration (FDA) approved for use in interscalene brachial plexus nerve blockade as well as infiltrative blockade. Delivery in this form is reported to provide up to 72 hours of extended-release bupivacaine. Exparel's use as a regional anesthetic has also become increasingly common and has shown promise when utilized in Anterior Cruciate Ligament (ACL) reconstruction.

Timeline

Start: 2023-08-21
Primary completion: 2024-10-30
Completion: 2024-10-30

Publications

Johns WL, Voskeridjian A, Miltenberg B, Muchintala R, Dodson CC, Cohen SB, Salvo J, Sherman M, Ciccotti MG, Hammoud S. Regional Anesthesia Utilizing Liposomal Bupivacaine, With or Without Dexamethasone, Provides Excellent Pain Control and Minimizes Opioid Consumption Following Anterior Cruciate Ligament Reconstruction. Orthop J Sports Med. 2026 Jan 8;14(1):23259671251401596. doi: 10.1177/23259671251401596. eCollection 2026 Jan.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Bupivacaine	Other / unclassified	30 ml	Other
Comparator	Dexamethasone	Small molecule	10 mg	—
Comparator	Bupivacaine	Other / unclassified	5 ml	Other

Indications

No indication recorded.